Disease Introduction
Here, "heart disease" is a broad term, referring to the comprehensive management of organic heart disease and common cardiovascular diseases, including hypertensive heart disease, coronary heart disease, valvular heart disease, cardiomyopathy, and heart failure. Patients often present with chest tightness, chest pain, palpitations, shortness of breath, and decreased exercise tolerance. The general principles of treatment are early screening and diagnosis, standardized control of risk factors such as blood pressure, blood lipids, and blood sugar, stratification of the condition for selecting medication, interventional procedures, or surgery, and long-term follow-up management.
Cutting-edge high-precision diagnostic and treatment technologies
- AI-assisted blood pressure reduction : The National Center for Cardiovascular Diseases and Fuwai Hospital have developed an intelligent hypertension doctor system that integrates guidelines to recommend medications and referrals for primary care physicians. After one year of management, patients’ systolic blood pressure decreased by an average of 15 mmHg, and the blood pressure control rate reached 75%.
- Mobile health intervention : The Fuwai team conducted a cluster randomized controlled trial in 4,533 high-risk cardiovascular individuals in 127 villages. The intervention, led by village doctors, using a WeChat mini-program and wearable bracelets for 12 months, significantly reduced the 10-year and lifetime risk of cardiovascular disease. The results were published in the British Medical Journal in 2025.
- Pan-vascular Management Center : Taking the Pan-vascular Disease Management Center (PVMC) as the starting point, it integrates multidisciplinary collaboration with specialized revascularization and full-cycle management. The first batch of demonstration units has been established nationwide to achieve the integration of prevention, treatment and rehabilitation.
- AI Closed-Loop Management : The Fuwai team developed the AI-enhanced Coronary Heart Disease Management Platform (AIM-CHD), which realizes closed-loop management of risk factors and dynamic risk stratification follow-up through AI voice calling, test report recognition and automatic collection of wearable data.
- AI-assisted diagnosis and treatment of cardiomyopathy : Cardiovascular MRI will assist in the precise diagnosis and treatment of cardiomyopathy by 2025. SCMR, RSNA, and ESCR jointly released a scientific statement on "AI in cardiac CT and MRI" and standardized AI assessment tools.
